In vitro activities of cellulase and ceftazidime, alone and in combination against Pseudomonas aeruginosa biofilms.
Biofilm inhibition
Ceftazidime
Cellulase
MBEC
Pseudomonas aeruginosa
Journal
BMC microbiology
ISSN: 1471-2180
Titre abrégé: BMC Microbiol
Pays: England
ID NLM: 100966981
Informations de publication
Date de publication:
16 12 2021
16 12 2021
Historique:
received:
08
02
2021
accepted:
02
12
2021
entrez:
17
12
2021
pubmed:
18
12
2021
medline:
28
1
2022
Statut:
epublish
Résumé
Biofilms are a main pathogenicity feature of Pseudomonas aeruginosa and has a significant role in antibiotic resistance and persistent infections in humans. We investigated the in vitro activities of antibiotic ceftazidime and enzyme cellulase, either alone or in combination against biofilms of P. aeruginosa. Both ceftazidime and cellulase significantly decreased biofilm formation in all strains in a dose-dependent manner. Combination of enzyme at concentrations of 1.25, 2.5, 5, and 10 U/mL tested with 1/16× MIC of antibiotic led to a significant reduction in biofilm biomass. Cellulase showed a significant detachment effect on biofilms at three concentrations of 10 U/mL, 5 U/mL, and 2.5 U/mL. The MIC, MBC, and MBEC values of ceftazidime were 2 to 4 µg/mL, 4 to 8 µg/mL, and 2048 to 8192 µg/mL. When combined with cellulase, the MBECs of antibiotic showed a significant decrease from 32- to 128-fold. Combination of the ceftazidime and the cellulase had significant anti-biofilm effects, including inhibition of biofilm formation and biofilm eradication in P. aeruginosa. These data suggest that glycoside hydrolase therapy as a novel strategy has the potential to enhance the efficacy of antibiotics and helps to resolve biofilm-associated wound infections caused by this pathogen.
Sections du résumé
BACKGROUND
Biofilms are a main pathogenicity feature of Pseudomonas aeruginosa and has a significant role in antibiotic resistance and persistent infections in humans. We investigated the in vitro activities of antibiotic ceftazidime and enzyme cellulase, either alone or in combination against biofilms of P. aeruginosa.
RESULTS
Both ceftazidime and cellulase significantly decreased biofilm formation in all strains in a dose-dependent manner. Combination of enzyme at concentrations of 1.25, 2.5, 5, and 10 U/mL tested with 1/16× MIC of antibiotic led to a significant reduction in biofilm biomass. Cellulase showed a significant detachment effect on biofilms at three concentrations of 10 U/mL, 5 U/mL, and 2.5 U/mL. The MIC, MBC, and MBEC values of ceftazidime were 2 to 4 µg/mL, 4 to 8 µg/mL, and 2048 to 8192 µg/mL. When combined with cellulase, the MBECs of antibiotic showed a significant decrease from 32- to 128-fold.
CONCLUSIONS
Combination of the ceftazidime and the cellulase had significant anti-biofilm effects, including inhibition of biofilm formation and biofilm eradication in P. aeruginosa. These data suggest that glycoside hydrolase therapy as a novel strategy has the potential to enhance the efficacy of antibiotics and helps to resolve biofilm-associated wound infections caused by this pathogen.
Identifiants
pubmed: 34915848
doi: 10.1186/s12866-021-02411-y
pii: 10.1186/s12866-021-02411-y
pmc: PMC8675527
doi:
Substances chimiques
Anti-Bacterial Agents
0
Ceftazidime
9M416Z9QNR
Cellulase
EC 3.2.1.4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
347Informations de copyright
© 2021. The Author(s).
Références
J Med Microbiol. 2012 May;61(Pt 5):662-671
pubmed: 22301617
J Chin Med Assoc. 2018 Jan;81(1):7-11
pubmed: 29042186
Sci Adv. 2016 May 20;2(5):e1501632
pubmed: 27386527
Infez Med. 2018 Sep 1;26(3):226-236
pubmed: 30246765
Biotechnol Lett. 2011 Sep;33(9):1897-904
pubmed: 21618024
PLoS Genet. 2014 Jul 24;10(7):e1004518
pubmed: 25057820
J Infect Chemother. 2018 Jun;24(6):428-433
pubmed: 29449129
J Immunol. 2005 Dec 1;175(11):7512-8
pubmed: 16301659
Burns Trauma. 2013 Jun 18;1(1):5-12
pubmed: 27574616
Pol J Microbiol. 2013;62(3):327-30
pubmed: 24459841
J Biotechnol. 2014 Dec 10;191:121-30
pubmed: 25240440
Microbiol Mol Biol Rev. 2009 Jun;73(2):310-47
pubmed: 19487730
Open Microbiol J. 2017 Apr 28;11:53-62
pubmed: 28553416
J Antimicrob Chemother. 2014 Apr;69(4):1027-34
pubmed: 24408988
Pathog Dis. 2013 Apr;67(3):159-73
pubmed: 23620179
APMIS Suppl. 2013 May;(136):1-51
pubmed: 23635385
Antimicrob Agents Chemother. 2017 Jan 24;61(2):
pubmed: 27872074
Age Ageing. 2002 Mar;31(2):126-30
pubmed: 11937475
Mar Drugs. 2019 May 24;17(5):
pubmed: 31137680
Clin Microbiol Rev. 2006 Apr;19(2):403-34
pubmed: 16614255
BMC Microbiol. 2019 Dec 12;19(1):291
pubmed: 31830915
Int J Antimicrob Agents. 2009 Jun;33(6):525-31
pubmed: 19179053
Antimicrob Agents Chemother. 2009 Mar;53(3):1204-9
pubmed: 19064900
Peptides. 2014 Dec;62:32-7
pubmed: 25285879
Biofouling. 2003 Apr;19(2):77-85
pubmed: 14618691
Biochemistry (Mosc). 2011 Jun;76(6):622-35
pubmed: 21639842
Antimicrob Agents Chemother. 2019 May 24;63(6):
pubmed: 30988141
APMIS Suppl. 2014 Dec;(138):1-51
pubmed: 25399808
Nat Rev Microbiol. 2010 Sep;8(9):623-33
pubmed: 20676145
Cold Spring Harb Perspect Med. 2013 Apr 01;3(4):a010306
pubmed: 23545571
Adv Appl Microbiol. 2014;86:1-40
pubmed: 24377853
Chemotherapy. 2003 Jun;49(3):121-5
pubmed: 12815204
J Wound Ostomy Continence Nurs. 2008 May-Jun;35(3):273-80
pubmed: 18496083
PLoS One. 2020 Jun 25;15(6):e0235093
pubmed: 32584878
PLoS One. 2016 Oct 13;11(10):e0164622
pubmed: 27736961
Science. 1999 May 21;284(5418):1318-22
pubmed: 10334980
Clin Microbiol Rev. 2002 Apr;15(2):167-93
pubmed: 11932229
Sci Rep. 2018 Jul 16;8(1):10738
pubmed: 30013112
Biofilm. 2020 Sep 01;2:100037
pubmed: 33447822
BMC Res Notes. 2020 Jan 10;13(1):27
pubmed: 31924268
Mycoses. 2012 Jan;55(1):80-5
pubmed: 21668524
Infect Immun. 2008 Sep;76(9):4176-82
pubmed: 18591225
Curr Microbiol. 2014 May;68(5):635-41
pubmed: 24445333
Antimicrob Agents Chemother. 2013 Jan;57(1):196-204
pubmed: 23089750